Evolocumab injection outperforms oral ezetimibe in lowering LDL cholesterol risk
A new trial using real-world evidence found that the injectable drug evolocumab reduced heart attack risk by 20 percent compared to the oral medication ezetimibe.
Study compares two cholesterol drugs
Cardiologists often consider two long-approved options when statins are insufficient for managing LDL levels. One option is evolocumab, an injectable PCSK9 inhibitor sold by Amgen as Repatha. The other is ezetimibe, an oral absorption inhibitor previously marketed by Merck as Zetia.
Results favor the injection method
The new trial based on real-world data determined that Repatha was the winner in this comparison. This drug lowered heart attack risk by 20 percent more effectively than its oral counterpart. The study highlights a difference in effectiveness between the two different mechanisms and delivery routes.
Reported by one outlet
Only one outlet has published this. Nothing here has been checked against a second report, so read it as that outlet's account and follow the link below for the original.
Reported by
1 independent outlet. Headline as published. Links open the original report.